Serina's long-acting apomorphine advances to a second dose cohort

Serina Therapeutics reported on 9 September 2026 that an independent safety monitoring committee had reviewed the first cohort of its Phase 1b registrational study of SER-252 and recommended the trial proceed to the second, higher dose.

Apomorphine works in advanced Parkinson’s disease, but it does not last. Patients cycle between the drug working and the drug wearing off, and holding a steady dopaminergic level has meant continuous infusion. SER-252 attaches apomorphine to Serina’s POZ polymer so that a subcutaneous injection releases it slowly, which is what the company means by continuous dopaminergic stimulation.

Cohort 1 enrolled eight patients with motor fluctuations, randomised three to one between drug and placebo. The single-ascending-dose portion runs five such cohorts, 40 patients in all, followed by up to three multiple-dose cohorts of 48. Blinded observations so far show a pharmacokinetic profile consistent with prolonged apomorphine exposure and, on exploratory assessments, sustained periods of improved motor function in individual patients.

Blinded observations from eight patients at the lowest dose are not an efficacy result, and the company does not present them as one. What the committee cleared is the next rung of the dose ladder. Topline data are expected in the first half of 2027.